Earnings Call · Q2 FY2021·2021-08-07

Q2 21EPS +100.00%*·Rev n/aQ1 21EPS +100.00%*·Rev n/aQ4 20EPS -14.29%·Rev n/aQ3 20EPS -61.54%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Mark Namaroff — Executive Director of Investor Relations and Corporate Communications

Cheryl Blanchard — President and Chief Executive Officer

Mike Levitz — Chief Financial Officer

+2.6%1d on move date+2.0% vs SPY3d+1.5%5d+0.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access